Back to Search
Start Over
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
- Source :
- npj Precision Oncology, Vol 4, Iss 1, Pp 1-7 (2020), NPJ Precision Oncology
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Colorectal cancer
medicine.medical_treatment
32 Biomedical and Clinical Sciences
Brief Communication
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Stable Disease
FOLFOX
Internal medicine
Partial response
medicine
In patient
Cell destruction
Cancer
Chemotherapy
business.industry
3 Good Health and Well Being
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
3211 Oncology and Carcinogenesis
Colo-Rectal Cancer
3204 Immunology
030104 developmental biology
Circulating tumor DNA
030220 oncology & carcinogenesis
business
Digestive Diseases
Biomarkers
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- npj Precision Oncology, Vol 4, Iss 1, Pp 1-7 (2020), NPJ Precision Oncology
- Accession number :
- edsair.doi.dedup.....be1e11a76d5916547d68566e9f6ed4c9
- Full Text :
- https://doi.org/10.17863/cam.59973